Finland · Delayed Price · Currency is EUR Solar Foods Oyj Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw the start of commercial operations, key partnerships, and Factory 02's launch. Revenue was modest, with increased operating loss due to scaling, but order book and funding grew. Regulatory approvals and further commercialization are expected in 2026.
-
Transitioning to commercial scale, the company secured key U.S. supply agreements and advanced Factory 02 planning, targeting the high-growth health and performance protein market. Financials show stable losses amid heavy investment, with strong sustainability positioning and positive customer feedback.
Fiscal Year 2024
-
Hydrogen fermentation technology scaled successfully, with U.S. regulatory approval and public listing achieved. Operating loss increased due to Factory 01 and listing costs, but cash position remains strong. Additional EUR 10 million funding secured for R&D and U.S. expansion.
-
A five-year strategy targets U.S. market entry for Solein, a sustainable protein, leveraging hydrogen fermentation and modular factory scaling. Financial guidance projects strong EBITDA margins and rapid cost reductions, with positive EBITDA expected by 2030.
-
Key milestones achieved in H1 2024 include Factory 01 launch, US regulatory approval, and Nasdaq listing. Financially, the company maintains a strong cash position and expects profitability after scaling new factories. Commercialization and global expansion are the focus for the next strategy period.